The findings provide a new strategy for lung adenocarcinoma treatment: FFAR2 agonists (such as propionate) may serve as potential adjuvants to enhance the efficacy of immunotherapy or targeted therapy. Here, FFAR2 is linked to lung adenocarcinoma.